ESMAR Company opened the autumn season 2015 with active involvement in clinical studies. Four projects have started under our management in the Russian Federation. The principal activity took place in the following directions:

• We conducted the Initiation Visits and started patients’ recruitment for Phase II of the multicenter clinical study of the drug to treat Allergic Rhinitis (Sponsor— Russian pharmaceutical company);

• We successfully submitted to Regulatory Authorities of the Russian Federation two new projects of Phase III of multicenter clinical studies of the drug to treat Onychomycosis and Nail Psoriasis (Sponsor—European pharmaceutical company);

• We started preparations to submit for approval of the multicenter clinical study of the drug to treat Breast Cancer (Sponsor—European pharmaceutical company);

• We also conduct active patients’ recruitment for Phase II and Phase III of international clinical studies in Pneumonia, Mucoviscidosis, Asthma and COPD (Sponsor—European pharmaceutical company);

• Patients’ recruitment for Phase I for the drug in surgery area is successfully completed (Sponsor — domestic company);

• The update of the Regulatory Requirements database is completed according to changes adopted by FL 61.